These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31810924)

  • 21. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin.
    Lehmann SG; Seve M; Vanwonterghem L; Michelland S; Cunin V; Coll JL; Hurbin A; Bourgoin-Voillard S
    J Proteomics; 2019 Mar; 195():114-124. PubMed ID: 30660770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells.
    Liao CH; Tzeng YT; Lai GM; Chang CL; Hu MH; Tsai WL; Liu YR; Hsia S; Chuang SE; Chiou TJ; Wang LM; Whang-Peng J; Yao CJ
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32751169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.
    Ishibashi M; Neri S; Hashimoto H; Miyashita T; Yoshida T; Nakamura Y; Udagawa H; Kirita K; Matsumoto S; Umemura S; Yoh K; Niho S; Tsuboi M; Masutomi K; Goto K; Ochiai A; Ishii G
    Sci Rep; 2017 Apr; 7():46662. PubMed ID: 28429795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.
    Cui Z; Liu Z; Zeng J; Zhang S; Chen L; Zhang G; Xu W; Song L; Guo X
    Life Sci; 2019 May; 224():23-32. PubMed ID: 30902544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
    Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
    J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
    Tang X; Jiang J; Zhu J; He N; Tan J
    Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
    Mei L; Chen Y; Wang Z; Wang J; Wan J; Yu C; Liu X; Li W
    Br J Pharmacol; 2015 May; 172(9):2232-45. PubMed ID: 25521075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
    Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
    Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib.
    Yuan J; Zhang N; Yin L; Zhu H; Zhang L; Zhou L; Yang M
    Sci Rep; 2017 Dec; 7(1):17814. PubMed ID: 29259263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
    Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
    PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting
    Wang Z; Pan L; Yu H; Wang Y
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29592872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
    Zhang J; Qu Z; Yao H; Sun L; Harata-Lee Y; Cui J; Aung TN; Liu X; You R; Wang W; Hai L; Adelson DL; Lin L
    Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of m
    Liu S; Li Q; Li G; Zhang Q; Zhuo L; Han X; Zhang M; Chen X; Pan T; Yan L; Jin T; Wang J; Lv Q; Sui X; Xie T
    Cell Death Dis; 2020 Nov; 11(11):969. PubMed ID: 33177491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
    Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
    Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.